UY35771A - Tienouracil-carboxamidas cíclicas y su uso - Google Patents

Tienouracil-carboxamidas cíclicas y su uso

Info

Publication number
UY35771A
UY35771A UY0001035771A UY35771A UY35771A UY 35771 A UY35771 A UY 35771A UY 0001035771 A UY0001035771 A UY 0001035771A UY 35771 A UY35771 A UY 35771A UY 35771 A UY35771 A UY 35771A
Authority
UY
Uruguay
Prior art keywords
prevention
treatment
tienouracil
diseases
preparation
Prior art date
Application number
UY0001035771A
Other languages
English (en)
Inventor
Lindner Niels
Dr Michael Härter
Dr Bernd Kalthof
Dr Klemens Lustig
Dr Raimund Kast
Frank Süssmeier
Dr Pierre Wasnaire
Dr Martina Delbeck
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35771A publication Critical patent/UY35771A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de 2,4-dioxo-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-carboxamida ("Tienouracil"-carboxamidas), a procedimientos para su preparación, a su uso solos o combinados para el tratamiento y/o la prevención de enfermedades así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, en particular para el tratamiento y/o la prevención de enfermedades pulmonares y del sistema cardiocirculatorio.
UY0001035771A 2013-10-07 2014-10-03 Tienouracil-carboxamidas cíclicas y su uso UY35771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13187487 2013-10-07
EP14152518 2014-01-24

Publications (1)

Publication Number Publication Date
UY35771A true UY35771A (es) 2015-04-30

Family

ID=51655757

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035771A UY35771A (es) 2013-10-07 2014-10-03 Tienouracil-carboxamidas cíclicas y su uso

Country Status (24)

Country Link
US (2) US9604996B2 (es)
EP (1) EP3055313B1 (es)
JP (1) JP2016532721A (es)
KR (1) KR20160065957A (es)
CN (1) CN105793267B (es)
AP (1) AP2016009128A0 (es)
AU (1) AU2014334040A1 (es)
BR (1) BR112016007238A2 (es)
CA (1) CA2926223A1 (es)
CR (1) CR20160155A (es)
CU (1) CU20160044A7 (es)
DO (1) DOP2016000076A (es)
EA (1) EA201600318A1 (es)
ES (1) ES2659043T3 (es)
IL (1) IL244751A0 (es)
MX (1) MX2016004250A (es)
NI (1) NI201600047A (es)
PE (1) PE20160562A1 (es)
PH (1) PH12016500608A1 (es)
SG (1) SG11201602397XA (es)
TN (1) TN2016000121A1 (es)
TW (1) TW201607950A (es)
UY (1) UY35771A (es)
WO (1) WO2015052065A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015342017B2 (en) * 2014-11-03 2020-02-06 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
KR20190049691A (ko) * 2016-07-07 2019-05-09 카듀리온 파마슈티칼스, 엘엘씨 심부전의 치료 방법
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
RU2019111357A (ru) * 2016-09-23 2020-10-23 Байер Акциенгезельшафт N3-циклически замещенные тиеноурацилы и их применение
WO2024037532A1 (zh) * 2022-08-16 2024-02-22 深圳市康哲生物科技有限公司 一种噻吩并嘧啶酮衍生物的盐型及晶型

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
PT1107973E (pt) 1998-08-28 2004-03-31 Astrazeneca Ab Novas tieno¬2,3-d| pirimidinodionas processo para a sua preparacao e sua utilizacao em terapia
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
JP2004518732A (ja) 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
ATE468339T1 (de) * 2001-12-20 2010-06-15 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
WO2006083005A1 (ja) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
US20070208040A1 (en) 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
KR101077295B1 (ko) * 2006-05-18 2011-10-26 에프. 호프만-라 로슈 아게 아데노신 ａ2ｂ 수용체 길항물질로서의 티아졸로-피라미딘/피리딘 우레아 유도체
WO2008070529A2 (en) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2008115912A1 (en) 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US7947629B2 (en) * 2007-08-06 2011-05-24 Schlumberger Technology Corporation Method of acidizing sandstone formations
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
ES2453474T3 (es) 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Derivados de aminopirazina y medicamento correspondiente
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
PL3628320T3 (pl) 2011-11-11 2022-07-25 Gilead Apollo, Llc Inhibitory acc i ich zastosowania

Also Published As

Publication number Publication date
EP3055313A1 (de) 2016-08-17
CN105793267B (zh) 2018-02-06
NI201600047A (es) 2016-09-21
BR112016007238A2 (pt) 2017-08-01
US9604996B2 (en) 2017-03-28
DOP2016000076A (es) 2016-05-15
IL244751A0 (en) 2016-04-21
KR20160065957A (ko) 2016-06-09
MX2016004250A (es) 2016-07-12
US20160244461A1 (en) 2016-08-25
TN2016000121A1 (en) 2017-10-06
CU20160044A7 (es) 2016-09-30
CN105793267A (zh) 2016-07-20
AP2016009128A0 (en) 2016-04-30
WO2015052065A1 (de) 2015-04-16
CR20160155A (es) 2016-07-21
US20170145029A1 (en) 2017-05-25
AU2014334040A1 (en) 2016-04-28
SG11201602397XA (en) 2016-05-30
JP2016532721A (ja) 2016-10-20
EA201600318A1 (ru) 2016-09-30
TW201607950A (zh) 2016-03-01
PH12016500608A1 (en) 2016-06-13
ES2659043T3 (es) 2018-03-13
CA2926223A1 (en) 2015-04-16
EP3055313B1 (de) 2017-11-22
PE20160562A1 (es) 2016-06-05

Similar Documents

Publication Publication Date Title
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
DOP2014000160A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
UY36064A (es) Derivados quirales de ácido ciclopentancarboxílico 2,5-disustituidos y su uso
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
DOP2015000290A (es) Benzoxazoles sustituidos
HN2010001125A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2014002857A1 (es) Uso de 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1) en el tratamiento de trastornos con sangrado uterino y hemorragias; sistema intrauterino que comprende 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1).
CU20130078A7 (es) Ácidos 1-bencicloalquilcarboxílicos sustituidos y su uso
IN2013MU03855A (es)
CR20120445A (es) Ariltriazolonas ligadas a bisarilo y su uso
TH1401006421A (th) สารประกอบสำหรับการใช้ในการผลิตยาสำหรับการรักษาโรคผิวหนังที่ตอบสนองต่อสเตียรอยด์

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211215